News | Cardiac Diagnostics

The American Medical Society for Sports Medicine (AMSSM) last week released a new position statement on cardiovascular pre-participation screening for athletes. The statement discusses current evidence and knowledge gaps while offering recommendations and future directions.

Home September 13, 2016
Home
News | Vascular Closure Devices

September 12, 2016 — Vivasure Medical announced last week that the company has completed a Series C financing of €16.2M ...

Home September 12, 2016
Home
News | Cardiac Diagnostics

A Saint Louis University researcher has received a grant to study the effects of treating post-traumatic stress disorder (PTSD) on cardiovascular and metabolic health. Jeffrey Scherrer, Ph.D., associate professor in Family and Community Medicine, received $2,348,320 from the National Heart, Lung, and Blood Institute of the National Institutes of Health (NIH).

Home September 12, 2016
Home
News | Venous Therapies

Veniti Inc. has closed on $25 million in Series D equity financing from Boston Scientific Corp. The funds will allow Veniti to complete the VIRTUS Trial and regulatory filing for the Vici Venous Stent System. The trial is being performed under a U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE). The company also intends to expand product development and commercial operations.

Home September 12, 2016
Home
News | Congenital Heart

September 9, 2016 — New research published Sept. 8 in the Open Access journal PLOS Biology reports the role of genes in ...

Home September 09, 2016
Home
News | Artificial Heart

Carmat announced that the first implantation of its bioprosthetic artificial heart within the framework of the PIVOTAL study has been carried out. The implantation was conducted in accordance with the authorizations obtained from the ANSM (French national agency for the safety of medicines and health products) and CPP (patient protection committee).

Home September 09, 2016
Home
News | Heart Valve Technology

Six-month preclinical data from trials of a Xeltis bioabsorbable aortic conduit were presented at the 2016 scientific meeting of the International Society for Applied Cardiovascular Biology (ISACB). The data was presented by Prof. Frederick Schoen, M.D., Ph.D., senior pathologist and executive vice chairman, Department of Pathology at Brigham and Women’s Hospital, and professor of pathology and health sciences and technology, Harvard Medical School.

Home September 09, 2016
Home
News | Blood Testing

September 8, 2016 — Prevencio Inc. announced that data on its new clinical and multi-protein panel to diagnose ...

Home September 08, 2016
Home
News | Electronic Medical Records (EMR)

Technological and administrative obstacles are significantly cutting into available time for physicians to engage with patients. Nearly half a physician’s office day is now filled by data entry into electronic medical records (EHRs) and administrative desk work, according to a new time-motion study conducted by experts at the American Medical Association (AMA) and Dartmouth-Hitchcock healthcare system. The study results were published in the Annals of Internal Medicine.

Home September 07, 2016
Home
News | Ultrasound Imaging

September 7, 2016 — Toshiba America Medical Systems Inc. announced that its Aplio 500 Platinum ultrasound system will be ...

Home September 07, 2016
Home
News | EP Lab

September 7, 2016 — St. Jude Medical Inc. (SJM) has filed a lawsuit against Muddy Waters Consulting LLC, Muddy Waters ...

Home September 07, 2016
Home
Case Study | Cardiovascular Information Systems (CVIS)

With any new system implementation in a healthcare system, there is a fear of downtime and potential adverse impact on ...

Home September 06, 2016
Home
News | Dave Fornell

September 5, 2016 — Lombard Medical Inc., a company focused on endovascular aneurysm repair (EVAR) of abdominal aortic ...

Home September 06, 2016
Home
News | Left Atrial Appendage (LAA) Occluders

St. Jude Medical Inc. announced the start of the St. Jude Medical Amplatzer Amulet IDE trial of the company’s Amplatzer Amulet Left Atrial Appendage (LAA) Occluder. The trial will evaluate the safety and effectiveness of the device, used to close the LAA in patients diagnosed with non-valvular atrial fibrillation (AF). The first implant of the study took place at North Mississippi Medical Center in Tupelo, Miss., by Jim Stone, M.D.

Home September 02, 2016
Home
Videos | Heart Failure

This video, provided by Respicardia, demonstrates the Remede System is a pacemaker-like implantable device. It is ...

Home September 02, 2016
Home
Subscribe Now